DNTH
Dianthus Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+12/100
Last price
84.90
▼ 3.14 (3.57%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
89.44
Prev close
88.04
Day high
88.58
Day low
83.19
Volume
1.35M
Market cap
$4.78B
P/E (TTM)
—
52W range
32.22 – 117.88
Day trading desk
Gap from prior close
+1.59%
Prior close 88.04
VWAP
85.34
-0.52% from price
Relative volume
2.18×
Unusually busy
Session range
7.52%
83.18 – 89.44
Position in range
27%
Near session low
ATR (14D)
4.71
5.55% of price
Prior day high
89.58
PDH
Prior day low
86.09
PDL
Bid / ask spread
—
Quote not published
Session volume
1.78M
Avg 815.91K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.02%
-4.0%
1M
-21.00%
-22.2%
3M
-12.92%
-17.4%
6M
-0.93%
-19.1%
YTD
+107.23%
+93.0%
1Y
+144.42%
+128.0%
3Y
+524.73%
+442.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DNTH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+15.00K
Net buying
Buy transactions
12
334.03K shares
Sell transactions
11
319.03K shares
Net transactions
+23
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
69.36K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | RANDHAWA SIMRAT Officer |
CONVERSION | 23.12K | $477.05K | Direct |
| Sep 1, 26 | RANDHAWA SIMRAT Officer |
SELL | 23.12K | $2.46M | Direct |
| Aug 19, 26 | READ SIMON J. Director |
CONVERSION | 2.78K | $51.00K | Direct |
| Aug 19, 26 | READ SIMON J. Director |
SELL | 2.78K | $326.55K | Direct |
| Aug 13, 26 | VENESS ADAM M General Counsel |
CONVERSION | 15.00K | $272.55K | Direct |
| Aug 10, 26 | READ SIMON J. Director |
CONVERSION | 2.78K | $50.99K | Direct |
| Aug 10, 26 | VENESS ADAM M General Counsel |
CONVERSION | 20.00K | $357.60K | Direct |
| Aug 10, 26 | MCGEORGE ANNE Director |
CONVERSION | 7.75K | $97.00K | Direct |
| Aug 10, 26 | READ SIMON J. Director |
SELL | 2.78K | $304.23K | Direct |
| Aug 10, 26 | VENESS ADAM M General Counsel |
SELL | 20.00K | $2.21M | Direct |
| Aug 10, 26 | MCGEORGE ANNE Director |
SELL | 7.75K | $844.82K | Direct |
| Aug 7, 26 | GARCIA MARINO Chief Executive Officer |
CONVERSION | 166.00K | $1.40M | Direct |
| Aug 7, 26 | GARCIA MARINO Chief Executive Officer |
SELL | 166.00K | $17.95M | Direct |
| Jul 9, 26 | SAVITZ RYAN Chief Financial Officer |
CONVERSION | 31.25K | $680.29K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARR EDWARD |
Officer | 0 | Conversion of Exercise of derivative security |
GARCIA MARINO |
Chief Executive Officer | 65.29K | Conversion of Exercise of derivative security |
MCGEORGE ANNE |
Director | 0 | Conversion of Exercise of derivative security |
RANDHAWA SIMRAT |
Officer | 4.00K | Conversion of Exercise of derivative security |
READ SIMON J. |
Director | 0 | Conversion of Exercise of derivative security |
SAVITZ RYAN |
Chief Financial Officer | 0 | Conversion of Exercise of derivative security |
SOTEROPOULOS PAULA |
Director | 0 | Conversion of Exercise of derivative security |
VENESS ADAM M |
General Counsel | 15.00K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$4.78B
Enterprise value$3.89B
Revenue (TTM)$1.90M
Gross profit$1.90M
EBITDA$-217.72M
Net income$-192.25M
EPS (TTM)$-4.11
Free cash flow$-92.21M
Total cash$886.81M
Total debt$1.29M
Book value / share$21.39
Shares outstanding55.93M
Float55.85M
Short % of float18.11%
Dividend yield0.00%
Beta (5Y)0.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E-18.52
PEG ratio—
Price / sales—
Price / book3.99
EV / revenue2,043.73
EV / EBITDA-17.87
Gross margin100.00%
Operating margin-8079.11%
Profit margin0.00%
Return on equity-26.06%
Return on assets-17.69%
Debt / equity0.11
Current ratio26.10
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.04M | $6.24M | $2.83M | $6.42M | -67.3% |
| Operating revenue | $2.04M | $6.24M | $2.83M | $6.42M | -67.3% |
| Research & development | $145.64M | $83.11M | $32.84M | $29.38M | +75.2% |
| Selling, general & admin | $34.33M | $24.99M | $18.16M | $6.74M | +37.4% |
| Total operating expense | $179.97M | $108.10M | $51.00M | $36.12M | +66.5% |
| Operating income | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -74.7% |
| Net interest income | $16.12M | $17.36M | $4.76M | $1.15M | -7.2% |
| Pre-tax income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -91.1% |
| Net income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -91.1% |
| Net income to common | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -91.1% |
| Basic EPS | -4.20 | -2.55 | -8.45 | -1.92 | -64.7% |
| Diluted EPS | -4.20 | -2.55 | -8.45 | -1.92 | -64.7% |
| EBIT | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -74.7% |
| EBITDA | -$177.50M | -$101.45M | -$47.82M | -$29.56M | -75.0% |
| Basic shares | 38.62M | 33.31M | 5.15M | 14.82M | +15.9% |
| Diluted shares | 38.62M | 33.31M | 5.15M | 14.82M | +15.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $51.09M | $22.79M | $132.32M | $15.37M | +124.1% |
| Cash & short-term investments | $404.30M | $275.24M | $173.72M | $75.49M | +46.9% |
| Accounts receivable | $52.00K | $0 | — | — | — |
| Total current assets | $409.44M | $280.90M | $177.45M | $82.03M | +45.8% |
| Property, plant & equipment | $1.63M | $1.75M | $800.00K | $956.00K | -6.5% |
| Total assets | $530.92M | $374.01M | $179.41M | $83.11M | +42.0% |
| Total current liabilities | $30.73M | $18.45M | $9.63M | $8.22M | +66.6% |
| Total debt | $1.39M | $1.49M | $585.00K | $788.00K | -7.0% |
| Total liabilities | $37.52M | $21.53M | $10.54M | $9.45M | +74.3% |
| Retained earnings | -$336.73M | -$174.39M | -$89.42M | -$45.87M | -93.1% |
| Shareholder equity | $493.40M | $352.48M | $168.87M | $73.66M | +40.0% |
| Working capital | $378.71M | $262.45M | $167.82M | $73.81M | +44.3% |
| Net tangible assets | $493.40M | $352.48M | $168.87M | $73.66M | +40.0% |
| Shares issued | 43.22M | 31.12M | 14.82M | 14.82M | +38.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -91.1% |
| Depreciation & amortisation | $428.00K | $412.00K | $355.00K | $147.00K | +3.9% |
| Stock-based compensation | $22.79M | $12.89M | $2.90M | $1.52M | +76.8% |
| Change in working capital | $16.73M | -$351.00K | $4.86M | -$1.65M | +4,865.2% |
| Operating cash flow | -$129.06M | -$78.18M | -$36.86M | -$29.07M | -65.1% |
| Capital expenditure | -$213.00K | -$105.00K | -$110.00K | -$139.00K | -102.9% |
| Investing cash flow | -$122.83M | -$286.81M | $20.25M | -$59.82M | +57.2% |
| Financing cash flow | $280.13M | $255.62M | $133.57M | $96.68M | +9.6% |
| Free cash flow | -$129.27M | -$78.28M | -$36.97M | -$29.21M | -65.1% |
| End cash position | $51.25M | $23.02M | $132.39M | $15.43M | +122.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $761.00K | $463.00K | $284.00K | $396.00K | $193.00K | +64.4% |
| Operating revenue | $761.00K | $463.00K | $284.00K | $396.00K | $193.00K | +64.4% |
| Research & development | $48.69M | $34.53M | $59.90M | $32.49M | $26.25M | +41.0% |
| Selling, general & admin | $13.56M | $12.47M | $9.93M | $8.20M | $8.87M | +8.7% |
| Total operating expense | $62.24M | $47.00M | $69.83M | $40.68M | $35.12M | +32.4% |
| Operating income | -$61.48M | -$46.53M | -$69.54M | -$40.29M | -$34.93M | -32.1% |
| Net interest income | $11.54M | $6.26M | $5.27M | $3.66M | $3.40M | +84.2% |
| Pre-tax income | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -23.0% |
| Net income | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -23.0% |
| Net income to common | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -23.0% |
| Basic EPS | -0.90 | -0.85 | -1.43 | -0.97 | -0.88 | -5.9% |
| Diluted EPS | -0.90 | -0.85 | -1.43 | -0.97 | -0.88 | -5.9% |
| EBIT | -$61.48M | -$46.53M | -$69.54M | -$40.29M | -$34.93M | -32.1% |
| EBITDA | -$61.38M | -$46.46M | -$69.44M | -$40.19M | -$34.83M | -32.1% |
| Basic shares | 56.03M | 48.03M | 44.97M | 37.79M | 35.82M | +16.6% |
| Diluted shares | 56.03M | 48.03M | 44.97M | 37.79M | 35.82M | +16.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.55M | $627.67M | $51.09M | $55.98M | $13.24M | -82.4% |
| Cash & short-term investments | $886.81M | $1.11B | $404.30M | $402.61M | $257.39M | -20.2% |
| Accounts receivable | $106.00K | $1.23M | $52.00K | $5.00M | $39.00K | -91.4% |
| Total current assets | $897.54M | $1.12B | $409.44M | $413.82M | $263.61M | -19.9% |
| Property, plant & equipment | $1.64M | $1.57M | $1.63M | $1.49M | $1.58M | +4.7% |
| Total assets | $1.21B | $1.25B | $530.92M | $577.45M | $326.08M | -2.7% |
| Total current liabilities | $34.39M | $38.28M | $30.73M | $23.86M | $20.09M | -10.2% |
| Total debt | $1.29M | $1.36M | $1.39M | $1.28M | $1.33M | -5.6% |
| Total liabilities | $41.25M | $45.57M | $37.52M | $30.99M | $23.00M | -9.5% |
| Retained earnings | -$427.78M | -$377.56M | -$336.73M | -$272.30M | -$235.53M | -13.3% |
| Shareholder equity | $1.17B | $1.20B | $493.40M | $546.45M | $303.08M | -2.4% |
| Working capital | $863.15M | $1.08B | $378.71M | $389.97M | $243.51M | -20.2% |
| Net tangible assets | $1.17B | $1.20B | $493.40M | $546.45M | $303.08M | -2.4% |
| Shares issued | 54.80M | 54.58M | 43.22M | 42.85M | 32.18M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -23.0% |
| Depreciation & amortisation | $107.00K | $76.00K | $97.00K | $99.00K | $99.00K | +40.8% |
| Stock-based compensation | $11.90M | $10.60M | $5.98M | $5.79M | $5.71M | +12.2% |
| Change in working capital | -$5.01M | $2.22M | $12.48M | $2.85M | $3.05M | -326.2% |
| Operating cash flow | -$48.98M | -$28.86M | -$46.98M | -$30.55M | -$23.89M | -69.7% |
| Capital expenditure | -$181.00K | -$10.00K | -$138.00K | -$5.00K | -$46.00K | -1,710.0% |
| Investing cash flow | -$478.52M | -$133.97M | $37.20M | -$201.28M | $26.45M | -257.2% |
| Financing cash flow | $10.38M | $739.41M | $4.88M | $274.51M | $568.00K | -98.6% |
| Free cash flow | -$49.16M | -$28.87M | -$47.12M | -$30.56M | -$23.94M | -70.3% |
| End cash position | $110.72M | $627.84M | $51.25M | $56.15M | $13.47M | -82.4% |
Options analytics
Put / call volume
0.26
Call-heavy session
Put / call open interest
0.23
Positioning, not flow
Max pain
100.00
+17.1% from spot
ATM implied vol
77.9%
Nearest strike to spot
Skew (10% OTM)
+17.7%
Puts bid over calls
Call volume
81
Contracts, this expiry
Put volume
21
Contracts, this expiry
Heaviest call OI
100.00
159 contracts
Heaviest put OI
110.00
25 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.91 | -0.90 | +1.0% |
| Mar 2026 | -1.10 | -0.85 | +22.9% |
| Dec 2025 | -1.03 | -1.43 | -38.6% |
| Sep 2025 | -0.90 | -0.97 | -8.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.95 | 10 | $366.42K | -7.5% |
| Next quarter | -1.11 | 10 | $281.19K | -1.0% |
| Current year | -3.81 | 11 | $1.87M | -8.2% |
| Next year | -4.61 | 11 | $1.77M | -5.1% |
Analyst targets & ownership
Mean target$140.80
High target$200.00
Low target$122.00
Implied upside65.84%
Analyst count15
ConsensusSTRONG BUY
Strong buy / Buy1 / 15
Hold0
Sell / Strong sell0 / 0
Held by insiders0.12%
Held by institutions127.88%
Institutions holding364
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
88.57
-4.15% from price
SMA 20
95.50
-10.57% from price
SMA 50
104.00
-17.88% from price
SMA 100
97.48
-12.91% from price
SMA 200
81.60
+4.66% from price
EMA 12
90.61
-6.30% from price
EMA 26
95.86
-11.43% from price
EMA 50
98.68
-13.96% from price
RSI (14)
26.3
Oversold
MACD (12,26,9)
-5.25
Hist -0.70
ATR (14)
4.71
5.52% of price
Realised vol 30D
33.2%
Annualised
Bollinger upper
110.70
20, 2σ
Bollinger lower
80.29
20, 2σ
50 / 200 cross
Golden
104.00 vs 81.60
Trend bias
Above 200
+4.66%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.86
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
33.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.4%
Peak to trough
Max drawdown 5Y
-95.7%
Peak to trough
ATR 14
4.71
5.52% of price
Beta (reported)
0.18
5Y monthly, from filing
Short interest
Shares short
8.83M
Prior 8.42M
Change vs prior
+4.9%
Shorts adding
% of float
18.11%
Elevated
% of shares out
15.79%
Against total outstanding
Days to cover
15.0
Crowded exit
Float
55.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 11, 26 | JP Morgan | INITIATED | — | Overweight |
| Sep 4, 26 | Citigroup | INITIATED | — | Buy |
| Aug 6, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| May 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 9, 26 | Wolfe Research | INITIATED | — | Outperform |
| Mar 19, 26 | Wells Fargo | INITIATED | — | Overweight |
| Mar 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 10, 26 | Raymond James | UPGRADE | Outperform | Strong Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-3ASR · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-05
Proxy Statements
DEFA14A · 2026-04-09
Corporate Changes & Voting Matters
8-K · 2026-03-26
Corporate Changes & Voting Matters
8-K · 2026-03-12
Headlines
Top Bank Names 6 Stocks With Major Catalysts Ahead
GuruFocus.com · 4d ago
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
GlobeNewswire · 8d ago
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Simply Wall St. · 13d ago
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run
Simply Wall St. · 13d ago
JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating
MT Newswires · 26d ago
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
Insider Monkey · 32d ago
UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
The Fly · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.